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Abstract
Carbohydrate deficient glycoprotein syndromes (CDGS) are inherited disorders in glycosylation. Isoelectric focusing of
serum transferrin is used as a biochemical indicator of CDGS; however, this technique cannot diagnose the molecular defect.
Even though phosphomannomutase (PMM) deficiency accounts for the great majority of known CDGS cases (CDGS type
Ia), newly discovered cases have significantly different clinical presentations than the PMM-deficient patients. These
differences arise from other defects affecting the biosynthesis of N-linked oligosaccharides in the endoplasmic reticulum and
in the Golgi compartment. The most notable is the loss of phosphomannose isomerase (PMI) (CDGS type Ib). It causes
severe hypoglycemia, protein-losing enteropathy, vomiting, diarrhea, and congenital hepatic fibrosis. In contrast to PMM-
deficiency, there is no developmental delay nor neuropathy. Most symptoms in the PMI-deficient patients can be successfully
treated with dietary mannose supplements. Another defect is the lack of glucosylation of the lipid-linked oligosaccharide
precursor. The clinical features of this form of CDGS are milder, but similar to, PMM-deficient patients. Yeast genetic and
biochemical techniques were critical in unraveling these disorders since many of the defective genes were known in yeast and
corresponding mutants were available for complementation. Yeast strains carrying mutations in the homologous genes are
likely to provide conclusive identification of the primary defects in novel CDGS types that affect the synthesis and transfer of
precursor oligosaccharides. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Carbohydrate de¢cient glycoprotein syndrome
(CDGS) is a generic name for a group of inherited
disorders with primary defects in glycoconjugate bio-
synthesis [1^3]. The disorders are usually detected by
alterations in proteins with N-linked oligosaccha-
rides, but other glycosylation pathways may also be
compromised [4]. This review highlights newly dis-
covered types of CDGS, their clinical manifestations,
e¡ective therapy, and implications for other diseases.
Much of this progress was possible because several of
the genes had already been identi¢ed in the yeast
Saccharomyces cerevisiae, and strains were available
for complementation analysis.
2. Features of the most common form of CDGS
CDGS patients have altered protein N-glycosyla-
tion [1,5^9]. Many of the known patients are defec-
tive in the enzyme phosphomannomutase (PMM)
that converts Man-6-P into Man-1-P as shown in
Fig. 1. The human enzyme has about 57% identity
to the yeast enzyme and is required for glycoprotein
synthesis. In both yeast and higher organisms, Man-
1-P is then converted into GDP-Man, which is used
to synthesize all mannose-containing glycoconju-
gates. Thus, defects in PMM are predicted to reduce
the amount of N-linked oligosaccharides, glycophos-
pholipid anchors, O-mannosylated proteins [10^13],
and proteins with the newly identi¢ed C-mannosyla-
tion [14^16]. The e¡ects of PMM de¢ciency have
only been examined so far in relation to N-linked
glycosylation, where they result in hypoglycosylation
of many glycoproteins. Serum glycoproteins are the
most frequently studied since they are readily avail-
able.
Although PMM-de¢cient patients share many
symptoms, these can vary among individual patients.
Not all of the symptoms are always present in each
individual. Typically, severe mental and psychomo-
tor retardation, characteristic dysmorphic features,
retinitis pigmentosa, gastrointestinal tract problems
leading to a failure to thrive and liver pathology
are displayed. Coagulation problems may arise due
to de¢ciencies in serum glycoproteins, including an-
tithrombin III (ATIII) and protein C. Some of the
patients must be tube-fed, and all have limited mobil-
ity. Mortality is about 20% within the ¢rst 2 years.
This disorder, called CDGS type 1a, and its clinical,
biochemical and genetic aspects are presented in [2]
of this volume. It is the best studied of all known
varieties of CDGS, since it was ¢rst described in 1980
and the primary defect was identi¢ed in 1995.
3. Serum transferrin IEF: an important tool for
identifying glycosylation disorders
If patients present with an aggregate of the symp-
toms described above, CDGS can be biochemically
con¢rmed using an isoelectric focusing (IEF) analysis
of serum transferrin [17^21]. As mentioned above,
transferrin is only one of many glycoproteins altered
in CDGS.
Transferrin is currently the most widely used bio-
chemical indicator of CDGS. It has two N-glycosyl-
ation sites which are usually occupied by disialylated
biantennery chains forming tetrasialo transferrin. If
entire N-linked chains are missing or, if correctly
added N-linked chains are not processed correctly
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[22^24], undersialylated forms with fewer sialic acids
will appear. This produces carbohydrate-de¢cient
transferrins (CDT) (Fig. 2). CDT is also seen in un-
controlled fructosemia, galactosemia or following
heavy alcohol consumption [25^29]. These latter
IEF alterations are temporary and appear to normal-
ize within a few weeks of beginning proper treat-
ment. Since a small number of transferrin molecules
have triantennary oligosaccharides due to increased
branching, more highly sialylated forms, e.g. penta-
and hexasialo, are also seen. These forms increase
temporarily during acute phase reactions and preg-
nancy [21].
Traditionally, a speci¢c IEF pattern has de¢ned
the two main types (1 and 2) of CDGS. The
PMM-de¢cient patients have been designated to
have a ‘type 1’ transferrin pattern characterized by
the prevalence of 4, 2 or no sialic acid residues on
transferrin, whereas transferrin species carrying 3 or
1 sialic acid residues are underrepresented in these
patients. This pattern is due to the complete absence
of N-linked oliogosaccharide chains on one or both
Fig. 1. Simpli¢ed pathway of lipid-linked oligosaccharide precursor synthesis showing known defects. The biosynthesis of Dol-P-P-oli-
gosaccharide precursor is altered in several di¡erent varieties of CDGS, Types Ia, Ib, and Ic. The known defects are indicated by the
boxes. The most common identi¢ed defect is a loss of the enzyme phosphomannomutase (PMM) which normally catalyzes the forma-
tion of Man-1-P from Man-6-P. PMM-de¢ciency results in severe mental and psychomotor retardation (type Ia). Another defect is
the loss of phosphomannose isomerase (PMI), resulting in a decrease of the formation of Man-6-P from Fru-6-P. However, Man-6-P
can also be generated directly from Man using hexokinase. Patients lacking PMI can have severe hypoglycemia, congenital hepatic ¢-
brosis, coagulopathy, severe diarrhea and vomiting (type Ib). Surprisingly, these patients do not show psychomotor retardation or pe-
ripheral neuropathy. Dietary mannose treatments can signi¢cantly improve the clinical condition of PMI-de¢cient patients, but thus
far have not shown improvement in PMM-de¢cient patients. A new type of CDGS, called type Ic, is a clinically milder version of
PMM de¢ciency. It is caused by the lack of formation of Glc1Man9GlcNAc2-P-P-Dol. This results from a defect in the K1,3-glucosyl-
transferase that adds the ¢rst Glc residue to the lipid-bound oligosaccharide chain. In yeast, the ALG6 gene product is responsible for
carrying out this reaction. Yeast mutants have also been identi¢ed for both PMM and PMI, and were important for identifying the
human de¢ciencies. The highly conserved early steps in N-linked oligosaccharide biosynthesis are likely to make yeast a critical tool
for unraveling other human glycosylation defects. Defects in PMM and PMI probably also a¡ect the synthesis of GPI anchors, C-
mannosylated and O-mannosylated proteins. K1,3-Glucosyltransferase de¢ciency is speci¢c for the N-linked pathway.
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of the Asn sites of transferrin and is explained by
incomplete glycosylation of the protein in the endo-
plasmic reticulum [22,23,30]. Based on studies in the
model system S. cerevisiae [31], de¢ciencies in many
di¡erent biosynthetic steps can potentially generate a
similar or identical transferrin IEF pattern. Patients
who do not have a PMM de¢ciency, such as those
described below, also have a ‘type 1’ IEF pattern.
Carbohydrate de¢cient transferrins (CDT) indicate
a glycosylation abnormality, but not the primary de-
fect. This complicates the use of transferrins to type
patients clinically. On the other hand, if only under-
sialylated transferrin (as detected by IEF) is used to
de¢ne altered glycosylation, then CDGS could po-
tentially include patients without the classical symp-
toms and presentations seen in PMM-de¢cient
CDGS patients. A biochemical IEF pattern de¢ni-
tion of CDGS allows eventual assignment of speci¢c
defective genes to the disease.
4. Another clinical variant of CDGS
A 6-year-old boy with normal PMM activity was
diagnosed with CDGS since his transferrin IEF pat-
tern was identical to that of PMM-de¢cient CDGS
patients. Surprisingly, this patient’s clinical pro¢le
was incompatible with known CDGS patients [32].
He did not have the typical neurologic, dysmorphic
or abnormal skeletal features seen in PMM-de¢cient
children. He showed failure to thrive, recurrent and
severe hypoglycemia, evidence of thrombotic lesions,
along with hepatic and gastrointestinal problems,
such as severe vomiting and diarrhea. His persis-
tently low antithrombin III level prompted transfer-
rin IEF analysis, in spite of the atypical clinical pre-
sentation.
The patient’s clinical history di¡ered from PMM-
de¢cient CDGS children, who are recognizable at or
soon after birth. This boy appeared normal at birth,
but at about 1 year of age he began having gastro-
intestinal problems such as vomiting, diarrhea, pro-
tein-losing enteropathy and partial villus atrophy in
the small intestine. This led to a possible diagnosis of
celiac disease, which is an allergic-like condition
caused by consuming gluten-containing products,
such as wheat. Strict dietary control gave marginal
improvement, but much less than that expected for
celiac patients. The intestinal biopsy showed evidence
of microthrombic lesions suggesting a dangerous
procoagulant state. Electron photomicrographs of
enterocytes showed that the ER was distended with
large amounts of unidenti¢ed precipitated proteins
¢lling the lumen. Since he was hypoalbuminemic,
he received periodic transfusions of albumin. Low
ATIII (10^30% of normal) and the evidence of
thromboses prompted anti-coagulant therapy to re-
duce the risk of clot formation. This may have
caused several bouts of serious intestinal bleeding.
One life-threatening bleeding episode led to compas-
sionate use of oral mannose therapy, based on
previous work showing that exogenous mannose
corrected underglycosylation of PMM-de¢cient ¢-
broblasts [33].
This patient has now been on oral mannose ther-
apy (0.1^0.15 g/kg) 3^5 times per day for 2 years.
The hypoglycemia, hypoalbuminemia, protein-losing
enteropathy, ATIII de¢ciency, and chronic symp-
toms permanently reversed within several months
of starting mannose (Fig. 3). His underglycosylated
transferrin and K1-antitrypsin IEF patterns essen-
tially returned to normal by 11 months (Fig. 4).
Thus, mannose appeared to reverse all the symp-
toms, but the metabolic basis was not identi¢ed until
the end of the ¢rst year of therapy.
Direct assay of ¢broblast and leukocyte lysates
Fig. 2. Comparison of transferrin IEF in control and CDGS
patients with di¡erent defects. Serum from control (left lane),
PMM-de¢cient (middle lane) and PMI-de¢cient (right lane) pa-
tients was analyzed for transferrin isoelectric focusing pattern.
In control, the major band is tetrasialo transferrin having two
N-linked chains each with two sialic acids. The patterns of the
two patients are identical even though they are caused by di¡er-
ent defects and have dramatically di¡erent clinical symptoms.
The patients have residual tetrasialo transferrin, but the absence
of one or both N-linked chains causes the appearance of disia-
lo- (middle band) and asialo- (lowest band) transferrin. The
number of sialic acids per molecule is shown on the right side.
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[32] showed that this patient has an 85^95% de¢-
ciency in phosphomannose isomerase (PMI) (fruc-
tose-6-PHmannose-6-P). PMI activity was also as-
sayed using intact cells by following the fate of
exogenous [2-3H]mannose. When [2-3H]mannose en-
ters the cell, it is phosphorylated to Man-6-P which
has only two fates. It can be incorporated into gly-
coconjugates and their precursors via the PMM re-
action, or it can be converted into fructose-6-P via
PMI. In the latter reaction, the label is permanently
lost as 3HOH. By comparing the relative incorpora-
tion of label into glycoconjugates including dolichyl-
pyrophosphate-linked oligosaccharides to that into
3HOH, the PMI activity in the mutant cell can be
measured relative to control cells (Fig. 5). This pa-
tient had about 16% residual PMI activity using this
assay, which has the advantage of being independent
of the imposed arti¢cial conditions required in the in
vitro assay. Leukocytes from the mother, father and
an una¡ected sib had heterozygous levels (34^65%)
of PMI activity when measured by the in vitro assay.
Human PMI had been cloned previously [34]
based on its homology to yeast. Loss of PMI is lethal
in yeast unless the cells are supplied with both man-
nose and glucose, showing that glucose is the major
if not the exclusive source for mannose [35]. Analysis
of the PMI from the parents and patient indicted
that the paternal allele carried a mutation at amino
acid 219 that converted an RCQ. This R is con-
Fig. 3. Protein levels in a CDGS type 1b patient before and
after mannose therapy. Prior to starting mannose therapy, the
patient su¡ered from reduced levels of ATIII and albumin re-
sulting from protein-losing enteropathy (fecal K1-antitrypsin),
and received periodic albumin and immunoglobulin transfu-
sions. Anticoagulant therapy (Marcumar) was included to re-
duce the risk of thromboses. At time ‘0’, mannose was given
orally 5 times a day at 100^150 mg/kg. Soon after beginning
mannose therapy, protein-losing enteropathy was reversed (top
panel), and the ATIII and albumin concentrations returned to
normal levels (horizontal line) (bottom panel).
Fig. 4. E¡ects of mannose therapy on the glycosylation of
transferrin and K1-antitrypsin in PMI-de¢cient patient. The top
panel shows serum transferrin IEF analysis of a PMM-de¢cient
CDGS patient (lane 1) and the PMI-de¢cient patient before
mannose therapy (lane 2) and then 11 (lane 3) and 21 (lane 4)
months after starting mannose therapy. Normal control (lane
5). In the two bottom panels, K1-antitrypsin was analyzed by
two-dimensional gel electrophoresis before mannose therapy be-
gan and then after 11 months of mannose therapy. Undersialy-
lated glycoforms (arrows) disappeared or were considerably re-
duced after mannose therapy. (From Ref. [32], used with
permission from J. Clin. Invest.)
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served in Candida albicans, Caenorhabditis elegans
and mouse PMI, but it does not appear to be located
in the active site of the enzyme. Active PMI is
thought to be a monomer and it is not known to
require binding to other proteins for catalytic activ-
ity. Expression of this abnormal allele in COS cells
showed 0^10% of normal activity compared to con-
trol. The maternal allele showed no mutation in the
coding region. This allele was greatly under-repre-
sented in RT-PCR clones derived from the patient.
This suggested that the maternal allele was ine⁄-
ciently transcribed or unstable. The maternal allele
probably accounted for very little active enzyme in
the patient. In line with this hypothesis, the mother’s
leukocytes had only 34% of normal PMI activity.
Both parents are asymptomatic.
Since this patient has the same transferrin pattern
as PMM-de¢cient patients who are de¢ned as type
1a, PMI de¢ciency has been designated type 1b.
5. Additional patients with PMI de¢ciency
Currently there are eight additional patients who
have been identi¢ed with PMI de¢ciency. In one
study [36], Jaeken et al. found two PMI de¢cient
patients with a similar clinical presentation. The ¢rst
patient had two mutations changing amino acid res-
idues conserved in S. cerevisiae and C. albicans PMI:
S102L and M138T. The Glu-137 position is probably
involved in binding Zn2, which is required for en-
zymatic activity. Unfortunately, this patient died at
age 4 years, prior to diagnosis and did not have an
opportunity for mannose therapy. Another patient
had very low PMI activity and an abnormal trans-
ferrin IEF pattern during the ¢rst several months of
life. He had severe vomiting and a spectrum of symp-
toms that included generalized hypotonia, megalo-
blastic anemia, liver dysfunction, low ATIII, and dif-
fuse hypodensity of white matter. No mutations were
reported for his PMI. At age 4 months, he began a
diet containing solid food such as vegetables, fruit
and meat. He subsequently stopped vomiting,
showed improved weight gain and muscle tone. The
biochemical parameters gradually improved and be-
came normal by 10 months of age. Transferrin IEF
normalized. He is now healthy with normal psycho-
motor development. This dramatic reversal was ten-
tatively attributed to changing to a diet containing
increased amounts of available mannose. Very little
is known about the availability of mannose in the
human diet, but some foods contain indigestible gal-
actomannans which have L-linked mannose residues
that are probably not easily hydrolyzed in the diges-
tive system [37^40]. However, it is di⁄cult to know
how much of an ‘indigestible’ carbohydrate would be
su⁄cient to provide mannose for PMI-de¢cient pa-
tients.
In another study, three teenage sibs of one consan-
guineous family had only V10^20% of normal PMI
activity [41]. They had milder symptoms than the
patient described above, and did not have demon-
strated protein-losing enteropathy. They had vomit-
ing and diarrhea that resulted in dehydration and
hospitalizations about once a year. The onset began
at 10 months of age in two of the patients and at 2
months of age in the other. Albumin was always low.
A liver biopsy was consistent with congenital hepatic
¢brosis. The hepatic symptoms were variable and
ranged from mildly enlarged liver to liver failure.
Mental and motor development were completely nor-
mal. The asymptomatic parents had heterozygous
PMI levels. Although the speci¢c defects have not
Fig. 5. Schematic view of [3H]mannose metabolism in PMI-de¢-
cient patient. When [2-3H]mannose enters the cell, it is phos-
phorylated to [2-3H]Man-6-P, which can be acted on by two
di¡erent enzymes, PMM or PMI. Reaction with PMM leads to
glycoconjugate synthesis. Reaction with PMI leads to the irre-
versible loss of 3HOH and further metabolism of non-labeled
Fru-6-P. Under these conditions, about 90% of the [2-3H]Man
is converted to 3HOH and 10% is found in glycoconjugates. In
PMI-de¢cient ¢broblasts, the proportion found in glycoconju-
gates increases to 84% and 3HOH is reduced to about 16%.
This assay provides an accurate in vivo measure of PMI activ-
ity within the cells.
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been localized within the PMI1 gene, it is clear that
the same PMI de¢ciency can generate a range of
intestinal and hepatic symptoms of variable severity.
The results of mannose therapy have not yet been
published.
Another PMI-de¢cient patient was a 2-month-old
child with hypoglycemia, vomiting, hepatomegaly,
elevated transaminases, diarrhea, low ATIII and
Factor XI, and hypoalbuminemia [42]. Hypoglyce-
mia was reported to result from hyperinsulinemia.
He developed a thrombosis from a central venous
catheter used for delivery of nutrients. Mannose ther-
apy (4U0.17 g/kg b.wt.) led to clinical improvement.
Sequencing of the cDNA revealed that the patient
was a compound heterozygote. The mutant PMI al-
leles were not expressed, so the deleterious e¡ects of
these mutations on enzyme activity are not proven.
The bene¢cial e¡ects of mannose therapy support the
lack of su⁄cient PMI activity.
A study on another PMI-de¢cient patient shows
signi¢cant improvement with mannose therapy [43].
In this case, a 2-year-old girl with V5^9% of normal
PMI activity showed protein-losing enteropathy, low
serum protein, generalized edema, severe hypoglyce-
mia, and elevated liver transaminases. She developed
a thrombosis, had reduced coagulation factors,
ATIII, and protein S. After 4 months of mannose
therapy, anemia, hypoalbuminemia and hypoglyce-
mia resolved. Elevated liver-derived transaminases
have decreased, but have not become normal. The
mutations have not been determined. A 14-year-old
patient with protein-losing enteropathy and hypogly-
cemia has been treated with 4U0.1 g mannose/kg
b.wt. for 5 months. Both clinical features improved
(CDG Family Network, unpublished, HTTP://
www.cdgs.com/).
Since mannose supplementation will probably be a
life-long therapy for PMI-de¢cient patients, side ef-
fects have to be carefully monitored. The only side
e¡ect that can be directly attributed to mannose is a
slight rise in glycated hemoglobin (HbA1c) in the
¢rst patient described above. Mannose is about ¢ve
times as active in non-enzymatic glycation as an
equivalent concentration of glucose [44]. The level
of HbA1c decreased when the mannose dosage was
reduced. There is a practical limit to the amount of
ingested mannose that patients can be given at any
one time since concentrations greater than about 0.2
g/kg b.wt. cause osmotic diarrhea in most people
[45,46].
Since the diagnosis and treatment of potentially
fatal PMI-de¢ciency is straightforward, it seems
very worthwhile to consider that previously diag-
nosed cases of idiopathic congenital hepatic ¢brosis,
hypoglycemia, coagulopathies, and failure to thrive
should be considered as potential PMI de¢ciencies.
Two case reports in the literature are likely to fall
under this umbrella [47,48] and in those cases, 4 of
the 5 patients from two families died from multiple
thromboses.
6. A novel CDGS type I caused by a de¢ciency in
glucosylation of the lipid-linked oligosaccharides
A novel type of CDGS was recently reported
based on the analysis of four related patients with
CDGS type I serum sialotransferrin pattern, presum-
ably resulting from the absence of entire N-linked
chains. These patients resembled the PMM-de¢cient
patients, but they showed considerably milder pre-
sentations. All of these patients had normal PMM
activity [49]. A detailed analysis of patient derived
¢broblasts revealed that glycoprotein biosynthesis
was drastically reduced in these cells. Inspection of
the biosynthesis of the dolichylpyrophosphate-linked
oligosaccharide Glc3Man9GlcNAc2, the substrate for
the N-linked glycosylation, showed an impaired glu-
cosylation of the oligosaccharide and resulted in the
accumulation of dolichylpyrophosphate-linked Man9-
GlcNAc2. It is well known that glucosylation of the
lipid-linked oligosaccharide is important for e⁄cient
transfer of the oligosaccharide to protein by the oli-
gosaccharyltransferase [50]. The impaired glucosyla-
tion of the lipid-linked oligosaccharide therefore
explained the hypoglycosylation of glycoproteins
observed in these patients. However, it was noted
that glucosylation of the oligosaccharide was not to-
tally absent in patient ¢broblasts because small, but
signi¢cant, amounts of fully assembled Glc3Man9-
GlcNAc2 were observed. This altered glucosylation
of the lipid-linked oligosaccharide can be caused by
a de¢ciency of the enzyme adding the ¢rst K1,3-
linked glucosyl residue to the Man9GlcNAc2 oligo-
saccharide. This enzyme, dolichyl-P-Glc:Man9Glc-
NAc2-PP-dolichol glucosyltransferase, transfers a
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glucosyl residue from dolichylphosphoglucose to
Man9GlcNAc2-PP-dolichol. Alternatively, impaired
dolichylphosphoglucose synthase activity can also
lead to the accumulation of dolichylpyrophosphate-
linked Man9GlcNAc2. To address this issue directly,
the cDNA encoding dolichylphosphoglucose syn-
thase and dolichyl-P-Glc:Man9GlcNAc2-PP-dolichol
glucosyltransferase from healthy individuals and pa-
tient ¢broblasts were isolated. The identi¢cation of
the cDNAs was based on the sequence of the corre-
sponding yeast loci, ALG5 [51] and ALG6 [52], re-
spectively. No mutation in the patient ALG5 cDNA
was found, however, a mutation changing an alanine
residue at position 333 to a valine residue was de-
tected in the patient ALG6 cDNA. This seemingly
minor change had important consequences for enzy-
matic activity, since expression of normal human
cDNA complements a deletion of the ALG6 locus
in yeast. However, expression of the mutant cDNA
was not able to complement the deletion in the
ALG6 locus. This ¢nding provided: (a) the proof
that the isolated cDNA encoded dolichyl-P-
Glc:Man9GlcNAc2-PP-dolichol glucosyltransferase
activity; and (b) the functional link between the mu-
tation found in these patients and the impaired glu-
cosylation of the oligosaccharide. Genotypic analysis
showed that all four related patients were homozy-
gous for the mutation in question. The parents of
two of these patients were heterozygous [69].
Recently, a 7-year-old girl with mental and psy-
chomotor retardation and coagulation problems
was reported [53]. Serum transferrin IEF also re-
vealed the same pattern as seen in the above patients,
but with normal PMM and PMI activities. A de-
tailed analysis of the lipid-bound oligosaccharides
showed the accumulation of Man9GlcNAc2-PP-doli-
chol in ¢broblasts from this patient. In addition, a
strongly reduced activity of the dolichyl-P-Glc:
Man9GlcNAc2-PP-dolichol glucosyltransferase was
measured in ¢broblast derived extracts. These results
suggest that also in this patient, a mutant ALG6
allele might be responsible for the disease.
It is important to note that this novel type of
CDGS is distinct from CDGS type Ia and Ib. It is
only expected to a¡ect N-linked protein glycosyla-
tion, whereas a de¢ciency in PMM and PMI also
alters the biosynthesis of GPI anchors as well as O-
and C-mannosylation in the ER. It will be interesting
to see whether speci¢c clinical manifestations can be
attributed to the di¡erent CDGS types.
Von Figura and co-workers named this case
CDGS type V; however, we suggest that it be called
type Ic. We propose a more simpli¢ed nomenclature
for CDGS that is still based on transferrin IEF, but
di¡erentiates the absence of entire chains from de-
fects in subsequent oligosaccharide processing. Type
I includes defects in the synthesis of precursors and
the addition of chains in the ER by oligosaccharyl-
transferase, whereas type II represents defects alter-
ing the processing of the N-linked oligosaccharide
after its transfer to protein by the oligosaccharyl-
transferase. This would accommodate the known
ways of creating de¢ciencies in glycosylation and
would allow a preliminary classi¢cation of novel
cases based on biochemical analysis (e.g. isoelectro-
focusing of serum transferrin). A precise classi¢ca-
tion of a given syndrome (e.g. CDGS type Ic) is
only possible when the defect is identi¢ed at a mo-
lecular level. The pleiotropic e¡ect of mutations al-
tering the pathway of N-linked glycosylation requires
such a stringent classi¢cation, but we are aware that
it does not simplify the clinician’s task of dealing
with the highly variable clinical presentations [7].
N-Linked protein glycosylation in the ER is a
complex pathway and the analysis of CDGS type I
has revealed a de¢ciency in this process as the pri-
mary cause for the disease. Biochemical analysis of
the pathway proved to be di⁄cult because it directly
involves very diverse biological macromolecules such
as lipids, oligosaccharides and proteins. Yeast molec-
ular genetics allowed signi¢cant progress in the anal-
ysis and characterization of the process (for a review,
see [31]) and brought to light a high degree of con-
servation of the pathway in eukaryotic cells. As
shown for the analysis of CDGS type Ic, this evolu-
tionary conservation makes it possible to apply the
yeast system as a tool to identify directly the primary
cause of di¡erent types of CDGS.
7. Are there other variations of CDGS?
About 25^30% of all diagnosed CDGS patients
with an altered transferrin IEF pattern have normal
PMM activity and therefore must have other defects.
PMM-de¢cient patients are clinically the best char-
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acterized of the group; they represent the diagnostic
standard. However, the clinical variations among the
non-PMM de¢cient patients are considerably broad-
er than seen within the PMM-de¢cient cases. Some
non-PMM de¢cient patients currently under investi-
gation were detected by keen-eyed clinicians who sus-
pected glycosylation abnormalities even though the
patients did not present the typical symptoms of
PMM de¢ciency.
Considering the large number of steps involved in
N-glycosylation, there are many possible lesions. Up
to 0.5^1% of the transcribed human genes may be
devoted to the production or recognition of glycosyl-
ated molecules [54]. Not all such defects might pro-
duce symptoms, of course. On the other hand, it
could mean that glycosylation-based disorders are
considerably more common than is currently appre-
ciated, as suggested in recent editorials [55,56] and
reviews [4]. Reports of several non-PMM cases with
the typical underglycosylation pattern seen for type 1
cases have appeared [57,58]. In one study [57], both
patients had serious respiratory problems, protein-
losing enteropathy and thrombocytopenia. Both
died soon after birth. The other report shows only
that the defect is not in PMM, but displayed an
altered transferrin IEF and unusual oligosaccharide
structures. This raises an important issue. The IEF
reveals only altered sialylation, it does not reveal the
structure of the oligosaccharide chain. Knowing the
structure may be of considerable bene¢t in trying to
assess the primary defect, but it might also mislead.
Some glycosyltransferases, such as sialyltransferase,
depend on glycosylation for full activity [59]. De-
creases in sialylation may be secondary to misglyco-
sylation caused by another defect in an earlier por-
tion of the pathway.
It is important to point out that not all glycosyla-
tion defects can be detected with serum transferrin
IEF, since transferrin has only a portion of known
types of N-linked chains. For instance, leukocyte ad-
hesion de¢ciency II [60,61] is literally a CDGS since
misglycosylated proteins are produced due to a lesion
in a general aspect of fucosylation. However, most
serum glycoproteins, including transferrin, are not
fucosylated and would not indicate altered fucosyla-
tion. Other diagnostic tests that do not rely on trans-
ferrin need to be developed to screen for other forms
of altered glycosylation.
8. Future directions
Additional defects in patients who show the same
transferrin IEF pattern as PMM-, PMI-, and gluco-
syltransferase-de¢cient patients continue to be found.
Work is in progress using the yeast system to analyze
such patients in much the same way it was used for
pin-pointing the K-glucosyltransferase de¢ciency.
Since humans and yeast share nearly all of the steps
for generating a dolichol-linked precursor and trans-
ferring it to protein, it is di⁄cult to imagine a more
complementary system for tracking down these de-
fects [31]. Biosynthesis of both the carbohydrate
chain and the lipid carrier would be amenable to
analysis in yeast, and defects in either pathway
would be expected to compromise glycosylation
and lead to other forms of CDGS [62^65].
Currently, PMM-de¢ciency is the most common
CDGS defect known; only a handful of patients de-
¢ne the other varieties. However, in contrast to
PMM-de¢cient patients who have been recognized
for nearly 20 years, the defects described here have
only been recognized for a very short time. The
populations of these new patients actually may be
greater than PMM-de¢cient patients. In addition,
some glycosylation defects may have already been
described in the medical literature, but were not
recognized as such. They may have been viewed as
idiopathic ‘variants’ or ‘types’ of well-known dis-
orders. A good example is congenital hepatic ¢brosis
[66] where at least some cases in the literature
can now be recognized as likely PMI de¢ciencies
[47,48]. Clinicians acutely aware of the importance
of glycosylation will be vital for identifying new
patients and for linking diseases to altered glycosyla-
tion. Some of these disorders may be treatable by
simple dietary therapy, but our paltry understand-
ing of direct use of monosaccharide therapy for gly-
cosylation diseases requires further development
[67,68].
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